A Phase 2 interventional study of Vabametkib and Lazertinib in Advanced Solid Tumors, sponsored by Abion Inc. Recruiting at 24 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-22.
Sponsored by Abion Inc · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
ABN401-003 is a Phase 2 clinical study to assess efficacy, safety, tolerability and pharmacokinetic profile of ABN401 (vabametkib) in specific populations of advance solid tumors with c-MET alterations as monotherapy.
This study will start with one cohort and it will be a parallel cohort expansion study.
Abion Inc is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Diagnosis:
For Cohort 2:
Treatment experience
While on study treatment and for 6 months after the last dose of study treatment, a patient must:
i. Have a negative highly sensitive (eg, beta-human chorionic gonadotropin [β-hCG]) pregnancy test at screening and within 72 hours before the first dose of study treatment, and agree to further pregnancy tests, ii. Practice at least 1 highly effective method of ; if oral contraceptives are used, a barrier method of contraception must also be used.
e. If a patient's partner is of childbearing potential, the participant must use a condom and partner of the participant must also be practicing a highly effective method of contraception. A vasectomized patient must still use a condom, but the partner is not required to use contraception.
<!-- -->
Cohort 1:
All patients should submit tumor tissue/block collected from fresh or have available archival formalin-fixed, paraffin-embedded tumor tissue specimen. The archival tissue must be:
For fresh biopsied sample, core needle biopsy is permitted. Samples from fine-needle aspiration (FNA) is not acceptable unless the result of MET exon 14 skipping from local testing is available.
Cohort 2:
Exclusion Criteria:
Prior therapy
a. Previous treatment with c-MET inhibitors or hepatocyte growth factor (HGF)-targeting therapy.
b. For Cohort 2, prior chemotherapy for advanced, recurrent, or setting.
Genetic analysis results:
Known active infection with (HIV), human T-cell leukemia virus, type (HTLV-1), virus (HBV), or virus (HCV), unless the patients fall into below categories (patients fall into one of the a, b, c category are eligible to participate)
HIV
✓ CD4+ cells ≥ 350 cells/µL
✓ No history of AIDS
✓ No history of opportunistic infection in the past 12 months
HCV
✓ Undetectable viral load (Participants positive for hepatitis C antibody are eligible only if polymerase chain reaction is negative for hepatitis C RNA)
Patients receiving treatment with medications that meet one of the following criteria and that cannot be discontinued specified period prior to the start of treatment with study drug and for the duration of the study.
For Vabametkib (Wash-out: 1 week)
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will receive vabametkib 800 mg, monotherapy, administered orally once daily in 21-day cycles
Drug: Vabametkib
Part 1 (Safety Run-in): Subjects will receive lazertinib 240 mg in combination with one of three assigned dose levels of vabametkib, administered orally once daily in 21-day cycles Part 2 (Random Dose Optimization): A maximum of two vabametkib dose levels will be evaluated in this part. Patients will be randomized in 1:1 ratio to vabametkib dose level 1 (selected from Part 1) plus the determined dose of lazertinib or dose level 2 (selected from Part 1) plus the determined dose of lazertinib Part 3 (Randomized Clinical Trial): Patients will be randomized in 1:1 ratio to optimized vabametkib dose (selected from Part 2) plus lazertinib or Standard of Care (SOC) arm. SOC arm will be decided by the time of Part 3 initiation
Drug: Vabametkib · Drug: Lazertinib
Tablets Route of Administration: Oral
Tablets Route of Administration: Oral
Cohort 1: Objective response rate (ORR) according to response evaluation criteria in solid tumors (RECIST)1.1 by Blinded Independent Central Review (BICR)
ORR is defined as the proportion of patients who experience a complete response (CR) or partial response (PR) as measured by RECIST 1.1
Time frame: Up to 12 months
Cohort 2 Part 1: Incidence of DLT (Dose Limiting Toxicity)
Time frame: Up to 12 months
Cohort 2 Part 2: Optimal dose of vabametkib and lazertinib combination for Part 3 based on the risk-benefit assessment considering both ORR (Objective Response Rate) and AE (Adverse Events)
Time frame: Up to 12 months
Cohort 2 Part 3: ORR (Objective Response Rate)
Time frame: Up to 12 months
Cohorts 1 & 2: Objective response rate (ORR) measured by RECIST 1.1 by BICR
ORR is defined as the proportion of patients who experience a CR or PR as measured by RECIST 1.1 by BICR
Time frame: Up to 12 months
Cohorts 1 & 2: Duration of response (DoR) as measured by RECIST 1.1 by BICR
DoR as measured by RECIST 1.1 by ICR and investigator will be used. DoR is defined as the time period from documentation of disease response to disease progression.
Time frame: Up to 12 months
Cohorts 1 & 2: Disease advanced control rate (DCR) as measured per RECIST 1.1 by BICR
DCR is defined as the proportion of patients who achieve CR, PR, and stable disease (SD) as measured per RECIST 1.1 by ICR and investigator
Time frame: Week 12
Cohorts 1 & 2: Progression-free survival (PFS) according to RECIST 1.1 by BICR
PFS defined as the time from first dose of vabametkib until disease progression according to RECIST 1.1 by investigator
Time frame: Up to 18 months
Cohorts 1 & 2: Overall survival (OS) according to RECIST 1.1
OS defined as the time from first dose of study drug until death from any cause
Time frame: Up to 18 months
Cohort 1: Incidence of AEs of vabametkib
Safety and tolerability will be a comprehensive evaluation of AEs based on: * Incidence of AEs (including grade 3 and 4 TEAEs) * Vital signs measurements * Clinical laboratory analyses * ECGs * Physical examination findings * Visual examinations * Concomitant medications monitored throughout the study
Time frame: Up to 12 months
Cohort 2: Incidence of AEs of vabametkib with lazertinib combination
Safety and tolerability will be a comprehensive evaluation of AEs based on: * Incidence of AEs (including grade 3 and 4 TEAEs) * Vital signs measurements * Clinical laboratory analyses * ECGs (electrocardiogram) * ECHO (Echocardiography) or MUGA (Multiple Gated Acquisition) scans * Physical examination findings * Visual examinations * Concomitant medications monitored throughout the study
Time frame: Up to 12 months
Cohorts 1 & 2: Intensive Sampling - Pharmacokinetic (PK) parameter from plasma vabametkib concentration - Tmax: Time to reach maximum concentration
Time frame: Cycle 1: Days 1, 2, 15, and 16 (pre-dose). Pre-dose on Day 1 from Cycle 2 Day 1 onward until disease progression (PD), or discontinuation of treatment for any other reason. Each cycle is 21 days (Up to approximately 6 years)
Cohorts 1 & 2: Sparse Sampling - Pharmacokinetic (PK) parameter from plasma vabametkib concentration - Tmax: Time to reach maximum concentration
Time frame: Cycle 1: Day 1, Even cycles: Day 1 until disease progression (PD) or discontinuation of treatment for any other reason. Each cycle is 21 days (Up to approximately 6 years)
Cohorts 1 & 2: Intensive Sampling - Pharmacokinetic (PK) parameter from plasma vabametkib concentration - Cmax: Maximum concentration
Time frame: Cycle 1: Days 1, 2, 15, and 16 (pre-dose). Pre-dose on Day 1 from Cycle 2 Day 1 onward until disease progression (PD), or discontinuation of treatment for any other reason. Each cycle is 21 days (Up to approximately 6 years)
Cohorts 1 & 2: Sparse Sampling - Pharmacokinetic (PK) parameter from plasma vabametkib concentration - Cmax: Maximum concentration
Time frame: Cycle 1: Day 1, Even cycles: Day 1 until disease progression (PD) or discontinuation of treatment for any other reason. Each cycle is 21 days (Up to approximately 6 years)
Cohorts 1 & 2: Intensive Sampling - Pharmacokinetic (PK) parameter from plasma vabametkib concentration - Ke: apparent first-order terminal elimination rate constant
Time frame: Cycle 1: Days 1, 2, 15, and 16 (pre-dose). Pre-dose on Day 1 from Cycle 2 Day 1 onward until disease progression (PD), or discontinuation of treatment for any other reason. Each cycle is 21 days (Up to approximately 6 years)
Cohorts 1 & 2: Sparse Sampling - Pharmacokinetic (PK) parameter from plasma vabametkib concentration - Ke: apparent first-order terminal elimination rate constant
Time frame: Cycle 1: Day 1, Even cycles: Day 1 until disease progression (PD) or discontinuation of treatment for any other reason. Each cycle is 21 days (Up to approximately 6 years)
Cohorts 1 & 2: Intensive Sampling - Pharmacokinetic (PK) parameter from plasma vabametkib concentration - T1/2: apparent first-order terminal elimination half-life
Time frame: Cycle 1: Days 1, 2, 15, and 16 (pre-dose). Pre-dose on Day 1 from Cycle 2 Day 1 onward until disease progression (PD), or discontinuation of treatment for any other reason. Each cycle is 21 days (Up to approximately 6 years)
Cohorts 1 & 2: Sparse Sampling - Pharmacokinetic (PK) parameter from plasma vabametkib concentration - T1/2: apparent first-order terminal elimination half-life
Time frame: Cycle 1: Day 1, Even cycles: Day 1 until disease progression (PD) or discontinuation of treatment for any other reason. Each cycle is 21 days (Up to approximately 6 years)
Cohorts 1 & 2: Intensive Sampling - Pharmacokinetic (PK) parameter from plasma vabametkib concentration - AUC0-t: area under the concentration-time curve from time zero to the last measurable concentration
Time frame: Cycle 1: Days 1, 2, 15, and 16 (pre-dose). Pre-dose on Day 1 from Cycle 2 Day 1 onward until disease progression (PD), or discontinuation of treatment for any other reason. Each cycle is 21 days (Up to approximately 6 years)
Cohorts 1 & 2: Sparse Sampling - Pharmacokinetic (PK) parameter from plasma vabametkib concentration - AUC0-t: area under the concentration-time curve from time zero to the last measurable concentration
Time frame: Cycle 1: Day 1, Even cycles: Day 1 until disease progression (PD) or discontinuation of treatment for any other reason. Each cycle is 21 days (Up to approximately 6 years)
Cohorts 1 & 2: Intensive Sampling - Pharmacokinetic (PK) parameter from plasma vabametkib concentration - AUC0-12: area under the concentration-time curve from time zero to 12 hr post-dose
Time frame: Cycle 1: Days 1, 2, 15, and 16 (pre-dose). Pre-dose on Day 1 from Cycle 2 Day 1 onward until disease progression (PD), or discontinuation of treatment for any other reason. Each cycle is 21 days (Up to approximately 6 years)
Cohorts 1 & 2: Sparse Sampling - Pharmacokinetic (PK) parameter from plasma vabametkib concentration - AUC0-12: area under the concentration-time curve from time zero to 12 hr post-dose
Time frame: Cycle 1: Day 1, Even cycles: Day 1 until disease progression (PD) or discontinuation of treatment for any other reason. Each cycle is 21 days (Up to approximately 6 years)
Cohorts 1 & 2: Intensive Sampling - Pharmacokinetic (PK) parameter from plasma vabametkib concentration - AUC0-24: area under the concentration-time curve from time zero to 24 hr post-dose
Time frame: Cycle 1: Days 1, 2, 15, and 16 (pre-dose). Pre-dose on Day 1 from Cycle 2 Day 1 onward until disease progression (PD), or discontinuation of treatment for any other reason. Each cycle is 21 days (Up to approximately 6 years)
Cohorts 1 & 2: Sparse Sampling - Pharmacokinetic (PK) parameter from plasma vabametkib concentration - AUC0-24: area under the concentration-time curve from time zero to 24 hr post-dose
Time frame: Cycle 1: Day 1, Even cycles: Day 1 until disease progression (PD) or discontinuation of treatment for any other reason. Each cycle is 21 days (Up to approximately 6 years)
Cohorts 1 & 2: Intensive Sampling - Pharmacokinetic (PK) parameter from plasma vabametkib concentration - AUC0-tau: area under the plasma concentration-time curve from time zero to next dosing
Time frame: Cycle 1: Days 1, 2, 15, and 16 (pre-dose). Pre-dose on Day 1 from Cycle 2 Day 1 onward until disease progression (PD), or discontinuation of treatment for any other reason. Each cycle is 21 days (Up to approximately 6 years)
Cohorts 1 & 2: Sparse Sampling - Pharmacokinetic (PK) parameter from plasma vabametkib concentration - AUC0-tau: area under the plasma concentration-time curve from time zero to next dosing
Time frame: Cycle 1: Day 1, Even cycles: Day 1 until disease progression (PD) or discontinuation of treatment for any other reason. Each cycle is 21 days (Up to approximately 6 years)
Cohorts 1 & 2: Intensive Sampling - Pharmacokinetic (PK) parameter from plasma vabametkib concentration - AUC0-∞: area under the plasma concentration-time curve from time zero to infinity
Time frame: Cycle 1: Days 1, 2, 15, and 16 (pre-dose). Pre-dose on Day 1 from Cycle 2 Day 1 onward until disease progression (PD), or discontinuation of treatment for any other reason. Each cycle is 21 days (Up to approximately 6 years)
Cohorts 1 & 2: Sparse Sampling - Pharmacokinetic (PK) parameter from plasma vabametkib concentration - AUC0-∞: area under the plasma concentration-time curve from time zero to infinity
Time frame: Cycle 1: Day 1, Even cycles: Day 1 until disease progression (PD) or discontinuation of treatment for any other reason. Each cycle is 21 days (Up to approximately 6 years)
Cohorts 1 & 2: Intensive Sampling - Pharmacokinetic (PK) parameter from plasma vabametkib concentration - %Extrap: percentage of AUC0-∞ obtained by extrapolation
Time frame: Cycle 1: Days 1, 2, 15, and 16 (pre-dose). Pre-dose on Day 1 from Cycle 2 Day 1 onward until disease progression (PD), or discontinuation of treatment for any other reason. Each cycle is 21 days (Up to approximately 6 years)
Cohorts 1 & 2: Sparse Sampling - Pharmacokinetic (PK) parameter from plasma vabametkib concentration - %Extrap: percentage of AUC0-∞ obtained by extrapolation
Time frame: Cycle 1: Day 1, Even cycles: Day 1 until disease progression (PD) or discontinuation of treatment for any other reason. Each cycle is 21 days (Up to approximately 6 years)
Cohorts 1 & 2: Intensive Sampling - Pharmacokinetic (PK) parameter from plasma vabametkib concentration - Cave: average concentration over a dosage interval
Time frame: Cycle 1: Days 1, 2, 15, and 16 (pre-dose). Pre-dose on Day 1 from Cycle 2 Day 1 onward until disease progression (PD), or discontinuation of treatment for any other reason. Each cycle is 21 days (Up to approximately 6 years)
Cohorts 1 & 2: Sparse Sampling - Pharmacokinetic (PK) parameter from plasma vabametkib concentration - Cave: average concentration over a dosage interval
Time frame: Cycle 1: Day 1, Even cycles: Day 1 until disease progression (PD) or discontinuation of treatment for any other reason. Each cycle is 21 days (Up to approximately 6 years)
Cohorts 1 & 2: Intensive Sampling - Pharmacokinetic (PK) parameter from plasma vabametkib concentration - FLUCP: fluctuation over a dosage interval
Time frame: Cycle 1: Days 1, 2, 15, and 16 (pre-dose). Pre-dose on Day 1 from Cycle 2 Day 1 onward until disease progression (PD), or discontinuation of treatment for any other reason. Each cycle is 21 days (Up to approximately 6 years)
Cohorts 1 & 2: Sparse Sampling - Pharmacokinetic (PK) parameter from plasma vabametkib concentration - FLUCP: fluctuation over a dosage interval
Time frame: Cycle 1: Day 1, Even cycles: Day 1 until disease progression (PD) or discontinuation of treatment for any other reason. Each cycle is 21 days (Up to approximately 6 years)
Cohorts 1 & 2: Intensive Sampling - Pharmacokinetic (PK) parameter from plasma vabametkib concentration - R: accumulation ratio
Time frame: Cycle 1: Days 1, 2, 15, and 16 (pre-dose). Pre-dose on Day 1 from Cycle 2 Day 1 onward until disease progression (PD), or discontinuation of treatment for any other reason. Each cycle is 21 days (Up to approximately 6 years)
Cohorts 1 & 2: Sparse Sampling - Pharmacokinetic (PK) parameter from plasma vabametkib concentration - R: accumulation ratio
Time frame: Cycle 1: Day 1, Even cycles: Day 1 until disease progression (PD) or discontinuation of treatment for any other reason. Each cycle is 21 days (Up to approximately 6 years)
Cohorts 1 & 2: Intensive Sampling - Pharmacokinetic (PK) parameter from plasma vabametkib concentration - CL/F: apparent systemic clearance
Time frame: Cycle 1: Days 1, 2, 15, and 16 (pre-dose). Pre-dose on Day 1 from Cycle 2 Day 1 onward until disease progression (PD), or discontinuation of treatment for any other reason. Each cycle is 21 days (Up to approximately 6 years)
Cohorts 1 & 2: Sparse Sampling - Pharmacokinetic (PK) parameter from plasma vabametkib concentration - CL/F: apparent systemic clearance
Time frame: Cycle 1: Day 1, Even cycles: Day 1 until disease progression (PD) or discontinuation of treatment for any other reason. Each cycle is 21 days (Up to approximately 6 years)
Cohorts 1 & 2: Intensive Sampling - Pharmacokinetic (PK) parameter from plasma vabametkib concentration - Vss/F: apparent volume of distribution at steady-state
Time frame: Cycle 1: Days 1, 2, 15, and 16 (pre-dose). Pre-dose on Day 1 from Cycle 2 Day 1 onward until disease progression (PD), or discontinuation of treatment for any other reason. Each cycle is 21 days (Up to approximately 6 years)
Cohorts 1 & 2: Sparse Sampling - Pharmacokinetic (PK) parameter from plasma vabametkib concentration - Vss/F: apparent volume of distribution at steady-state
Time frame: Cycle 1: Day 1, Even cycles: Day 1 until disease progression (PD) or discontinuation of treatment for any other reason. Each cycle is 21 days (Up to approximately 6 years)
Cohorts 1 & 2: Intensive Sampling - Pharmacokinetic (PK) parameter from plasma vabametkib concentration - Vz/F: apparent volume of distribution
Time frame: Cycle 1: Days 1, 2, 15, and 16 (pre-dose). Pre-dose on Day 1 from Cycle 2 Day 1 onward until disease progression (PD), or discontinuation of treatment for any other reason. Each cycle is 21 days (Up to approximately 6 years)
Cohorts 1 & 2: Sparse Sampling - Pharmacokinetic (PK) parameter from plasma vabametkib concentration - Vz/F: apparent volume of distribution
Time frame: Cycle 1: Day 1, Even cycles: Day 1 until disease progression (PD) or discontinuation of treatment for any other reason. Each cycle is 21 days (Up to approximately 6 years)
Cohorts 1 & 2: Intensive Sampling - Pharmacokinetic (PK) parameter from plasma vabametkib concentration - Cmin: minimum concentration during dosage interval
Time frame: Cycle 1: Days 1, 2, 15, and 16 (pre-dose). Pre-dose on Day 1 from Cycle 2 Day 1 onward until disease progression (PD), or discontinuation of treatment for any other reason. Each cycle is 21 days (Up to approximately 6 years)
Cohorts 1 & 2: Sparse Sampling - Pharmacokinetic (PK) parameter from plasma vabametkib concentration - Cmin: minimum concentration during dosage interval
Time frame: Cycle 1: Day 1, Even cycles: Day 1 until disease progression (PD) or discontinuation of treatment for any other reason. Each cycle is 21 days (Up to approximately 6 years)
Cohorts 1 & 2: Intensive Sampling - Pharmacokinetic (PK) parameter from plasma vabametkib concentration - Ctrough: concentration of the drug just prior to administration of next dosage
Time frame: Cycle 1: Days 1, 2, 15, and 16 (pre-dose). Pre-dose on Day 1 from Cycle 2 Day 1 onward until disease progression (PD), or discontinuation of treatment for any other reason. Each cycle is 21 days (Up to approximately 6 years)
Cohorts 1 & 2: Sparse Sampling - Pharmacokinetic (PK) parameter from plasma vabametkib concentration - Ctrough: concentration of the drug just prior to administration of next dosage
Time frame: Cycle 1: Day 1, Even cycles: Day 1 until disease progression (PD) or discontinuation of treatment for any other reason. Each cycle is 21 days (Up to approximately 6 years)
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2023 (actual). Primary completion is estimated for Feb 2029, 73 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lazertinib
Abion Inc